Publication in DIABETES
Aixin Yu, Isaac Snowhite, Francesco Vendrame, Michelle Rosenzwajg, David Klatzmann, Alberto Pugliese, and Thomas R. Malek, Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes, Diabetes June 2015 64:6 2172-2183

Publication in the Journal of Autoimmunity
Michelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, Adrien Six, Nicolas Dérian, Wahiba Chaara, Roberta Lorenzon, S. Alice Long, Jane H. Buckner, Georgia Afonso, Hang-Phuong Pham, Agnès Hartemann, Aixin Yu, Alberto Pugliese, Thomas R. Malek, David Klatzmann, Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients, Journal of Autoimmunity, Volume 58, April 2015, Pages 48–58

Publication in Current Diabetes Report
Michelle Rosenzwajg, Guillaume Churlaud, Agnès Hartemann, David Klatzmann, Interleukin 2 in the pathogenesis and therapy of type 1 diabetes, Current Diabetes Reports, October 2014, 14:553

Publication in The Lancet Diabetes and Endocrinology
Agnès Hartemann, Gilbert Bensimon, Christine A Payan, Sophie Jacqueminet, Olivier Bourron, Nathalie Nicolas, Michèle Fonfrede, Michelle Rosenzwajg, Claude Bernard, David Klatzmann, Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial, The Lancet Diabetes & Endocrinology, Volume 1, No. 4, p295–305, December 2013